Hormonal
GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) produce significant real-world weight loss, but effectiveness is substantially lower than in clinical trials due to high discontinuation rates (20-50%) and suboptimal dosing in routine care.
GLP-1 medications like semaglutide and tirzepatide are highly effective for weight loss, but their real-world success depends entirely on sticking with them. Many people stop early due to side effects or cost, leading to less weight loss than seen in trials. To get the best results, you must manage side effects (which often fade) and ensure you can afford the medication long-term. If you adhere to the full dose and stay on the drug, your weight loss can match what is seen in clinical trials.
The observed weight reduction in clinical practice overall tends to be lower than in randomized controlled trials; however, outcomes approach those seen in trials when focusing on highly adherent patients. Real-world studies demonstrate high discontinuation rates of GLP-1RAs (20%–50%) within the first year, and the use of much lower doses than those evaluated in clinical trials.
Why this rating
Based on a narrative review of multiple large observational epidemiological studies (cohorts, case-control) from diverse real-world settings.
Source
Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer <scp>GLP</scp> ‐ <scp>1RA</scp> ‐based weight‐loss therapies
Reimar W. Thomsen et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16364
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →